Advanced Search: Kidney

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201705069

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914

202002013

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)(A031801)

202003013

A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)

202003148

A single arm, multicenter, phase 2 trial to evaluate the efficacy of lenvatinib (LEN) in combination with pembrolizumab (KEYtruda) in subjects with locally advanced or metastatic Non-clear cell renal cell carcinoma (The LENKYN Trial)

201411135

Tissue, Blood, and Urine Acquisition for Molecular and Cellular Analysis and Collection of Health Information for Patients with Malignancies of the Genitourinary Tract

202006003

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

202006123

Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

202008066

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors

201902074

A Phase 1/2 Study to Compare NKTR-214 Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC)

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors